Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1905.

https://doi.org/10.1182/blood-2019-132035

Published: 2019

Journal Articles

Addition of the SMO Inhibitor Sonidegib to Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed to Respond or Lost Response to AZA Alone: Results of a Phase 1-2 Add-on Study By the GFM

Norbert Vey, MD PhD

Blood (2018) 132 (Supplement 1): 4368.

https://doi.org/10.1182/blood-2018-99-113529

Published: 2018

Journal Articles

Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

Ali Younas Khan, MD, Nimra Iftikhar, MD, Awais Ijaz, MD, Muhammad Junaid Tariq, MD, Faiza Jamil, MD, Arshia Akbar, MD, Anum Qureshi, Jemin Aby Jose, MD, Ahmad Kamal, MD, Muhammad Abu Zar, MD, Madeeha Shafqat, Insija Ilyas Selene, MBBS, Shehroz Aslam, MD, Faiz Anwer, MD

Blood (2018) 132 (Supplement 1): 5484.

https://doi.org/10.1182/blood-2018-99-115867

Published: 2018

Journal Articles

Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition with Sonidegib (LDE225) in Myeloid Malignancies

Raoul Tibes, MD PhD, Heidi Elizabeth Kosiorek, MS, Amylou Dueck, PhD, Jeanne Palmer, MD, James L. Slack, MD, Emily Ann Knight, NP, Saman Khalid Hashmi, MD, James M. Bogenberger, PhD, Darci Zblewski, CNP, William J. Hogan, MBBCh, Mark R. Litzow, MD, Ruben A Mesa, MD, James M. Foran, MD, Lisa Sproat, MD MSW, Aref Al-Kali, MD

Blood (2017) 130 (Supplement 1): 2629.

https://doi.org/10.1182/blood.V130.Suppl_1.2629.2629

Published: 2017

Journal Articles

Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

Vikas Gupta, MD FRCP, FRCPath, Claire N. Harrison, Hans Hasselbalch, MD, Lisa Pieri, MD PhD, Steffen Koschmieder, MD, Francisco Cervantes, Weichao Bao, PhD, Stacey Kalambakas, MD, Edric Atienza, MSHS, Prashanth Gopalakrishna, MBBS, MRCS, Florian H. Heidel, MD

Blood (2015) 126 (23): 825.

https://doi.org/10.1182/blood.V126.23.825.825

Published: 2015

Journal Articles

Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition in Myeloid Malignancies

Raoul Tibes, MD PhD, Heidi E. Kosiorek, MS, Amylou C. Dueck, PhD, Lisa Sproat, MD MSW, Jeanne Palmer, MD, James L. Slack, MD, Devinder Singh, MD, Eileen Gebhart, MSN, RN, ANP-BC, Emily Knight, RN, Shahrukh K. Hashmi, MD, Ryan A Wilcox, MD PhD, James M Bogenberger, PhD, Ruben A. Mesa, Aref Al-Kali, MD

Blood (2015) 126 (23): 1347.

https://doi.org/10.1182/blood.V126.23.1347.1347

Published: 2015

Journal Articles

Molecular Mechanism and Optimal Treatment Strategy in Acute Myeloid Leukemia with Resistance to Drugs and Radiation By NVP-LED225

Fanyi Meng, Xiaodong Li, Bingjie Ding, Kaikai Huang, Qiuhua Zhu, Fang Chen, Yufeng Zhu

Blood (2015) 126 (23): 3691.

https://doi.org/10.1182/blood.V126.23.3691.3691

Published: 2015

Journal Articles

Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

Vikas Gupta, MD FRCP, FRCPath, Steffen Koschmieder, MD, Claire N. Harrison, DM, FRCP, FRCPath, Francisco Cervantes, MD PhD, Florian H Heidel, MD, Mark Drummond, MD PhD, Jerome Rey, MD, Eunju Hurh, PhD, Weichao Bao, PhD, Anita Rampersad, Stacey Kalambakas, MD, Alessandro Maria Vannucchi, MD

Blood (2014) 124 (21): 712.

https://doi.org/10.1182/blood.V124.21.712.712

Published: 2014

Journal Articles

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

Frank Giles, MD MB, FRCPI, FRCPath, Sarina A. Piha-Paul, MD, Alexander I. Spira, PhD MD FACP, Fadi Braiteh, MD CPI, Julio Antonio Peguero, MD, Daniel L. Spitz, MD FACP, James A. Knost, MD, Lee Schwartzberg, MD FACP, Steven Stein, MD, August J. Salvado, MD, Claudia Lebedinsky, MD, Barinder Kang, PhD, Eric Slosberg, PhD

Blood (2014) 124 (21): 4818.

https://doi.org/10.1182/blood.V124.21.4818.4818

Published: 2014

Journal Articles

The Hedgehog Pathway As Targetable Vulnerability with 5-Azacitidine in MDS and AML

Raoul Tibes, MD PhD, Devora Delman, B.S., Nanna Hansen, M.S., Krisstina L. Gowin, DO, Ruben Mesa, MD, James M Bogenberger, PhD

Blood (2014) 124 (21): 4612.

https://doi.org/10.1182/blood.V124.21.4612.4612

Published: 2014

Journal Articles

MK2a Substrate-Selective p38 Inhibitor CMPD1 Selectively Synergizes with HDAC Inhibitors in CD34 + Cells from Myeloid Malignancies

James M Bogenberger, PhD, Nanna Hansen, M.S., Devora Delman, B.S., Ruben A. Mesa, MD, Raoul Tibes, MD PhD

Blood (2014) 124 (21): 2239.

https://doi.org/10.1182/blood.V124.21.2239.2239

Published: 2014

Journal Articles

Hh/IGF-1R/PI3K/Akt/MRP1 Pathway Induce Refractory Acute Myeloid Leukemia and Its Targeting Therpy

Kaikai Huang, Bingjie Ding, MD, Qingxiu Zhong, MD, Xuejie Jiang, MDPhD, Xiaodong Li, MD, Zhixiang Wang, MD, Fan Yi Meng, MD

Blood (2014) 124 (21): 3612.

https://doi.org/10.1182/blood.V124.21.3612.3612

Published: 2014

Journal Articles

Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis

Neha Bhagwat, B.S., Matthew D Keller, B.S., Raajit K. Rampal, M.D., Ph.D., Kaitlyn Shank, B.S., Elisa de Stanchina, PhD, Kristine Rose, PhD, Dereck Amakye, MD, Ross L. Levine, MD

Blood (2013) 122 (21): 666.

https://doi.org/10.1182/blood.V122.21.666.666

Published: 2013

Journal Articles

High Throughput Screening, With a Flow Cytometry Automated Platform (Ex vivo Biotech), To Identify Potential Combination Partners, For The JAK 2 Inhibitor Ruxolitinib

Alicia Arenas, Pilar Hernandez-Campo, Daniel Primo, Santiago Barrio, PhD, Rosa M. Ayala, MD, PhD, Joan Ballesteros, Joaquín Martínez-López, MD, PhD

Blood (2013) 122 (21): 2534.

https://doi.org/10.1182/blood.V122.21.2534.2534

Published: 2013

Journal Articles

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma

Simona Blotta, Jana Jakubikova, Teresa Calimeri, Aldo M. Roccaro, Nicola Amodio, Abdel Kareem Azab, Umberto Foresta, Constantine S. Mitsiades, Marco Rossi, Katia Todoerti, Stefano Molica, Fortunato Morabito, Antonino Neri, Piersandro Tagliaferri, Pierfrancesco Tassone, Kenneth C. Anderson, Nikhil C. Munshi

Blood (2012) 120 (25): 5002–5013.

https://doi.org/10.1182/blood-2011-07-368142

Published: 2012

Journal Articles

Modulation of Leukemic Stem Cell Self-Renewal and Cell Fate Decisions by Inhibition of Hedgehog Signalling in Human Acute Lymphoblastic Leukemia (ALL).

Fabian Lang, MD, Susanne Badura, Martin Ruthardt, MD, Michael A. Rieger, Oliver G. Ottmann, MD

Blood (2012) 120 (21): 2578.

https://doi.org/10.1182/blood.V120.21.2578.2578

Published: 2012

Journal Articles

Targeting the Hedgehog Signaling Pathway Limits the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Tetsuzo Tauchi, M.D., Seiichiro Katagiri, M.D., Seiichi Okabe, M.D., Yosuke Minami, MD, PhD, Tomoki Naoe, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2012) 120 (21): 531.

https://doi.org/10.1182/blood.V120.21.531.531

Published: 2012

Journal Articles

Blockade of the Hedgehog Signaling Pathway by the Novel Agent NVP-LDE225 Induces Differentiation, Prevents De-Differentiation and Inhibits Proliferation of Multiple Myeloma Stem Cells in Vitro

Shihong Yang, MSc, Ross D Brown, PhD, Yen S Loh, PhD, Hayley Suen, BSc (Hons), James Favaloro, BSc, John Gibson, MBBS, PhD, Phoebe Joy Ho, MBBS, DPhil, Douglas E Joshua, MBBS, DPhil

Blood (2012) 120 (21): 3950.

https://doi.org/10.1182/blood.V120.21.3950.3950

Published: 2012

Journal Articles

Combined Effects of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib In a Random Mutagenesis Screen

Tetsuzo Tauchi, M.D., Seiichi Okabe, M.D., Eishi Ashihara, M.D., Shinya Kimura, M.D., Taira Maekawa, M.D., Kazuma Ohyashiki, M.D.

Blood (2010) 116 (21): 595.

https://doi.org/10.1182/blood.V116.21.595.595

Published: 2010

Journal Articles

Inhibition of Chronic Myeloid Leukemia Stem Cells by the Combination of the Hedgehog Pathway Inhibitor LDE225 with Nilotinib

Bin Zhang, David Irvine, Yin Wei Ho, Silvia Buonamici, PhD, Paul Manley, PhD, Tessa L. Holyoake, PhD, FRCP, FRCPath, Mhairi Copland, PhD, BSc, MRCP, FRCPath, Ravi Bhatia, MD

Blood (2010) 116 (21): 514.

https://doi.org/10.1182/blood.V116.21.514.514

Published: 2010

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma

Addition of the SMO Inhibitor Sonidegib to Azacitidine in Patients with Higher Risk Myelodysplastic Syndrome (MDS) Who Failed to Respond or Lost Response to AZA Alone: Results of a Phase 1-2 Add-on Study By the GFM

Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis

Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition with Sonidegib (LDE225) in Myeloid Malignancies

Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

Phase I/IB Study of Azacitidine and Hedgehog Pathway Inhibition in Myeloid Malignancies

Molecular Mechanism and Optimal Treatment Strategy in Acute Myeloid Leukemia with Resistance to Drugs and Radiation By NVP-LED225

Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

The Signature Program, a Distinctive Tissue Agnostic Trial Model for Molecularly Pre-Selected Hematological and Solid Tumor Patients

The Hedgehog Pathway As Targetable Vulnerability with 5-Azacitidine in MDS and AML

MK2a Substrate-Selective p38 Inhibitor CMPD1 Selectively Synergizes with HDAC Inhibitors in CD34 + Cells from Myeloid Malignancies

Hh/IGF-1R/PI3K/Akt/MRP1 Pathway Induce Refractory Acute Myeloid Leukemia and Its Targeting Therpy

Improved Efficacy Of Combination Of JAK2 and Hedgehog Inhibitors In Myelofibrosis

High Throughput Screening, With a Flow Cytometry Automated Platform (Ex vivo Biotech), To Identify Potential Combination Partners, For The JAK 2 Inhibitor Ruxolitinib

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma

Modulation of Leukemic Stem Cell Self-Renewal and Cell Fate Decisions by Inhibition of Hedgehog Signalling in Human Acute Lymphoblastic Leukemia (ALL).

Targeting the Hedgehog Signaling Pathway Limits the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Blockade of the Hedgehog Signaling Pathway by the Novel Agent NVP-LDE225 Induces Differentiation, Prevents De-Differentiation and Inhibits Proliferation of Multiple Myeloma Stem Cells in Vitro

Combined Effects of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib In a Random Mutagenesis Screen

Inhibition of Chronic Myeloid Leukemia Stem Cells by the Combination of the Hedgehog Pathway Inhibitor LDE225 with Nilotinib

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only